Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Amortization of Deferred Charges (2016 - 2019)

Historic Amortization of Deferred Charges for Veracyte (VCYT) over the last 7 years, with Q2 2019 value amounting to $75000.0.

  • Veracyte's Amortization of Deferred Charges rose 83750.0% to $75000.0 in Q2 2019 from the same period last year, while for Mar 2020 it was $75000.0, marking a year-over-year increase of 13437.5%. This contributed to the annual value of $83000.0 for FY2019, which is 15937.5% up from last year.
  • Per Veracyte's latest filing, its Amortization of Deferred Charges stood at $75000.0 for Q2 2019, which was up 83750.0% from $8000.0 recorded in Q1 2019.
  • Over the past 5 years, Veracyte's Amortization of Deferred Charges peaked at $393000.0 during Q4 2017, and registered a low of $8000.0 during Q1 2018.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $12000.0 (2015), whereas its average is $59882.4.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 165454.55% in 2016, then tumbled by 9796.44% in 2018.
  • Veracyte's Amortization of Deferred Charges (Quarter) stood at $12000.0 in 2015, then soared by 1508.33% to $193000.0 in 2016, then skyrocketed by 103.63% to $393000.0 in 2017, then crashed by 97.96% to $8000.0 in 2018, then surged by 837.5% to $75000.0 in 2019.
  • Its Amortization of Deferred Charges stands at $75000.0 for Q2 2019, versus $8000.0 for Q1 2019 and $8000.0 for Q4 2018.